The Component Monitoring System and V24/V26 family of patient monitors is intended for the monitoring, recording, and alarming of multiple physiological parameters. The devices are indicated for use in health care facilities by healthcare professionals whenever there is a need for monitoring the physiologic parameters of adult, neonatal, and pediatric patients.

Device Description

The modification in this submission is the addition of an alternate blood analysis module to the current plug-in i-STAT module as a component to the CMS and V24/V26 family of patient monitors. The proposed M3560A Blood Analysis Portal System is substantially equivalent to the Diametrics IRMA Blood Analysis System but provides a plug-in interface instead of an RS232 interface connection. Only Diametrics analysis cartridges (IRMA cartridges) are used with this module. The new M3560A Blood Analysis Portal System is also smaller than the current Diametrics IRMA Blood Analysis System and does not operate via battery power.

AI/ML Overview

This 510(k) submission describes the M3560A Blood Analysis Portal System Plug-In Module for the Philips Component Monitoring System and V24/V26 family of patient monitors. It does not contain information about the acceptance criteria or a specific study proving the device meets acceptance criteria.

The document focuses on:

Device Description: The M3560A is an alternate blood analysis module that provides a plug-in interface, is smaller, and does not operate via battery power compared to its predicate device (Diametrics IRMA Blood Analysis System). It uses only Diametrics analysis cartridges (IRMA cartridges).
Intended Use: Monitoring, recording, and alarming of multiple physiological parameters for adult, neonatal, and pediatric patients in healthcare facilities by healthcare professionals.
Substantial Equivalence: It claims substantial equivalence to several predicate devices, including the Agilent Component Monitoring System, HP Viridia Component Monitoring System, M1032A VueLink Plug-In Module, Diametrics Medical, Inc. IRMA Blood Analysis System, HP Component Monitoring System, and i-STAT 200 Portable Clinical Analyzer.
Performance Standards: It states that components with arrhythmia and alarm capability remain compliant with 21 CFR Part 898, as they are unchanged from previous cleared submissions.
Fundamental Technology: The fundamental scientific technology is described as unchanged from the predicate devices.
Design Controls: Mentions that "Verification, validation, and testing activities will be successfully conducted and completed prior to commercialization to establish the safety, performance, and reliability characteristics of the M3560A Blood Analysis Portal System," including system level tests, integration tests, safety tests, and predicate device comparison. However, the details of these tests, including specific acceptance criteria or study results, are not provided in this summary.

Therefore, based on the provided text, the requested information regarding acceptance criteria and the study proving the device meets them cannot be extracted. The document states that testing will be conducted, implying this 510(k) summary is submitted before the detailed results of those tests are available or summarized for the FDA in this specific document.

Summary

{0}------------------------------------------------

11.0 510(k) Summary of Safety and Effectiveness

DEC 0 3 2001

This Special 510(k) submission notifies the FDA of our intention to introduce the M3560A I this beend o r the CMS and module for the CMS and V24/V26 family of patient monitors.

11.1 Manufacturer/Submitter

Denise Haley Quality and Regulatory Affairs Engineer

Philips Medizinsysteme Böblingen GmbH Point of Care Diagnostics Division Hewlett-Packard Str. 2 71034 Böblingen Germany

Telephone: 978-659-2701 978-685-5624 Fax: e-mail: denise haley@hsgmed.com

11.2 Establishment Registration Number 9610816

11.2 Manufacturing Site Addresses:

Philips Medizinsysteme Böblingen GmbH Hewlett-Packard Str. 2 71034 Böblingen Germany

AND

Diametrics Medical, Incorporated 2658 Patton Road Saint Paul, MN 55113-1136 USA

Sterilization Site 11.3

Does not apply.

11.4 Date

November 1, 2001

Philips Medical Systems

{1}------------------------------------------------

11.6 Device Name, Trade Name

Proprietary Name: Component Monitoring System and V24/V26 Patient Monitor, M3560A Blood Analysis Portal System Plug-In Module

Common Name: Patient Monitor Systems, Blood Analyzer Plug-In Module

Component Classifications:

Device classification information is presented in the following table. The FDA has placed all devices with arrhythmia and alarm capability in Class III. The

Classification	Procode	Description	Tier
870.1025	MHX	Monitor, Physiological, Patient (witharrhythmia detection or alarms)	3
870.1025	DSI	Detector and Alarm, Arrhythmia	3
870.2340	DPS	Electrocardiograph	2
870.1110	DSK	Computer, Blood Pressure	2
870.1120	DXQ	Cuff, Blood Pressure	2
870.1130	DXN	System, Measurement, Blood-Pressure,Non-Invasive	2
862.1170	CGZ	Electrode, Ion-Specific, Chloride	2
862.1120	CHL	Electrode Measurement, Blood Gases	2
862.1145	JFP	Electrode, Ion-Specific, Calcium	2
862.1665	JGS	Electrode, Ion-Specific, Sodium	2
862.1600	CEM	Electrode, Ion-Specific, Potassium	2
864.6400	GKG	Hematocrit	2
862.1770	CDS	Electrode, Ion-Specific, Urea Nitrogen	2

11.7 Performance Standards

Mandatory Standards:

21 CFR Part 898 establishes a performance standard for electrode lead wires and patient cables, and for arrhythmia detectors and alarms for the procodes and device classifications contained in the system and codified at 870.1025. These components of the CMS and V24/V26 Monitor Systems are unchanged from the previous submission and remain compliant. These components were previously cleared for commercial use in Premarket Notifications K000854 (cleared April 3, 2000), K993516 (cleared November 8, 1999), K980429 (cleared September 9,1998), and K991773 (cleared June 7, 1999).

{2}------------------------------------------------

11.8 Substantial Equivalence

The CMS and V24/V26 family of patient monitors with the M3560A Blood Analysis Portal System Module is substantially equivalent to the previously cleared devices listed below:

Manufacturer	Device	Model	510(k)
Agilent Technologies	Agilent Component Monitoring System	M1175A,M1176A,M1177A	K002758
Agilent Technologies	Agilent Component Monitoring System	M1175A,M1176A,M1177A,M1205A	K001722
Agilent Technologies	Agilent Component Monitoring System	M1175A,M1176A,M1177A,M3000AM3046A	K001333
Agilent Technologies	HP Viridia Component Monitoring System	M1175A,M1176A,M1177A	K992674
Hewlett-Packard	M1032A VueLink Plug-In Module	M1032A	K923682
Diametrics Medical, Inc.	IRMA Blood Analysis System	Series 2000	K981270
Hewlett-Packard	HP Component Monitoring System	M1175A,M1176A,M1177A	K882609
i-STAT	i-STAT 200 Portable Clinical Analyzer	i-STAT 200	K940918

11.9 Modification Description

11.10 Intended Use

{3}------------------------------------------------

11.12 Fundamental Technology

The fundamental scientific technology employed in the operation of this device has not
es and the states and the success of the red 2/2/2001). K001722 (cleared The fundamental scientric technivolegy on.groy on not 2002/2001), K001722 (cleared
changed from the predicate devices [K002758 (cleared 2/2/2001), K001722 (cleared changed from the predicate devices [K002750 (cleared 5/1/1998), and K940918 (cleared 5/10/1994)].

11.13 Design Controls

Verification, validation, and testing activities will be successfully conducted and completed Verification, validation, and establish the safety, performance, and reliability characteristics
prior to commercialization to establish the safety, performance, tests prior to commercialization to establish the barely, perten . Testing involves system level tests, of the M3560A Blood Analysis Forcal System : " compense to the many of the market testing.
integration tests, safety tests from hazard and for the prodicate devices to integration tests, salety lests from hazard unarysis, and of the predicate devices to demonstrate substantial equivalence.

ાપર

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol resembling a human figure or a bird in flight, composed of three curved lines.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 0 3 2001

Philips Medizinsysteme Böblingen GmbH c/o Ms. Denise Haley Philips Medical Systems, Inc. 3000 Minuteman Road Andover, MA 01810

Re: K013624

Trade Name: Component Monitoring System and V24/V26 Patient Monitor Family with M3560A Blood Analysis Portal System Plug-in Module Regulation Number: 21 CFR 870.1025 Regulation Name: Patient Physiological Monitor Regulatory Class: Class III (three) Product Code: MHX Dated: November 1, 2001 Received: November 5, 2001

Dear Ms. Haley:

We have reviewed your Section 510(k) premarket notification of intent to market the device n & nave roviewed your been wind the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for ass stated in the encreate) is the enactment date of the Medical Device Amendments, or to conninered pror to May 20, 1978, in cannon with the provisions of the Federal Food, Drug, de necs that have been require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The r ou may, are every mains of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it 11 your device to such additional controls. Existing major regulations affecting your device can may or subject to outsil Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{5}------------------------------------------------

Page 2 - Ms. Denise Haley

Please be advised that FDA's issuance of a substantial equivalence determination does not mean I lease oc advised that I Drive issual.to sever device complies with other requirements of the Act that I Dr Has Interes and regulations administered by other Federal agencies. You must of any I coural statutes and registments, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set Of K Fart 6077, mooning (21 CFR Part 820); and if applicable, the electronic forth in the quind of the provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) I mis letter will and w you'll ough finding of substantial equivalence of your device to a legally prematics notication. Thesults in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of additionally 21 Of 11 Parceles. Additionally, for questions on the promotion and advertising of Compinance at (301) 294-661 Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Oiner general mistmances, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

V. Van Tiem

James E. Dillard II Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

3.1 ODE Indications for Use Statement

Indications for Use Statement

510(k) Number: K013624
(if known)

Device Name: Component Monitoring System and V24/V26 Patient Monitor family with Device Namer Composis Portal System Plug-In Module

Indications for Usc:

The Component Monitoring System and V24/V26 family of patient monitors is intended for The Component Monitoring Oystem and of multiple physiological parameters. The devices the monitoring, recording, and alaming of maniped by healthcare professionals whenever there is a are indicated for use in licannelers of adult, neonatal, and pediatric patients.

PLEASE DO NOT WRITE BELOW THIS LINE--CONTINUE ON ANOTHER PAGE IF NEEDED

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

Over-The-Counter Use

Division of Cardiovascular & Respiratory Devices
510(k) Number K013424

November 1, 2001

Regulation Number and Section

§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).

(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.